PAMP
VKTX icon

Polar Asset Management Partners’s Viking Therapeutics VKTX Stock Holding History

Polar Asset Management Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,300
Closed -$228K – 826
2024
Q2 		$228K Buy
+4,300
New +$282K ﹤0.01% 449

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Polar Asset Management Partners's VKTX Position: Q3 2024 in Review

Polar Asset Management Partners sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 4,300 shares — an estimated $228K sold.

Polar Asset Management Partners first reported a position in VKTX in Q2 2024 and held it in 1 quarter. The position peaked at $228K in Q2 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Polar Asset Management Partners reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 4,300 Viking Therapeutics shares in Q3 2024, an estimated $228K.
  • Polar Asset Management Partners first reported a position in Viking Therapeutics in Q2 2024 and held it in 1 quarter.
  • Polar Asset Management Partners's Viking Therapeutics position peaked at $228K in Q2 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Polar Asset Management Partners's 13F filing for Q3 2024, filed 14 Nov 2024.